Articles
The enemy within

The enemy within

Sam Olsen warns that the greatest threat to Pharmaceutical and Biotech corporate Intellectual Property (IP) security comes from within.

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D